Press releases

Non Regulatory

December 30, 2014

Nxt2b extends loan to Oasmia

Regulatory

December 30, 2014

Publication of change in the total number of shares and votes in Oasmia

Non Regulatory

December 30, 2014

Oasmia receives a new MSEK 20 bank loan

Non Regulatory

December 18, 2014

Oasmia’s Chairman of the Board buys shares

Non Regulatory

December 17, 2014

Oasmia change to Mid Cap segment at Nasdaq Stockholm

Non Regulatory

December 12, 2014

Final result of Oasmia’s rights issue

Non Regulatory

December 10, 2014

Preliminary result of Oasmia’s rights issue

Regulatory

December 4, 2014

Prospectus addendum regarding Oasmia Pharmaceutical’s rights issue is now available

Non Regulatory

December 4, 2014

Interim report for the period May – October 2014

Regulatory

November 17, 2014

Prospectus, including new financial information, regarding Oasmia Pharmaceutical’s rights issue is now available

Regulatory

November 11, 2014

Oasmia Pharmaceutical AB announces a fully committed and underwritten rights issue of approximately SEK 176 million

Non Regulatory

October 21, 2014

Oasmia’s lead human oncology product Paclical shows a positive risk/benefit profile versus standard treatment in pivotal phase III clinical study

Non Regulatory

October 1, 2014

Communiqué from Oasmia’s Annual General Meeting 2014

Non Regulatory

September 30, 2014

Oasmia receives a new MSEK 40 bank loan

Non Regulatory

September 12, 2014

Oasmia considers secondary listing on NASDAQ USA

Regulatory

September 5, 2014

Interim report for the period May – July 2014

Non Regulatory

September 1, 2014

Correction of notice regarding notice of Annual General Meeting

Non Regulatory

September 1, 2014

Anders Blom new Executive Vice President in Oasmia

Non Regulatory

September 1, 2014

Notice convening the Annual General Meeting of Oasmia Pharmaceutical AB

Non Regulatory

August 21, 2014

The Oasmia Pharmaceutiacal Annual Report is now published

Regulatory

July 31, 2014

Publication of change in the total number of shares and votes in Oasmia

Non Regulatory

July 3, 2014

Oasmia successfully completes private placement of SEK 50 million

Non Regulatory

July 2, 2014

Oasmia announces launch of private placement of new shares

Non Regulatory

June 25, 2014

Oasmia signs agreement for patented technology XR-17

Non Regulatory

June 24, 2014

Oasmia extends its production agreement with Baxter

Non Regulatory

June 16, 2014

Oasmia’s Lead Human Product Paclical® Successfully Meets Primary Objective in Pivotal Phase III Clinical Study

Non Regulatory

June 5, 2014

Year-end report for the fiscal year May 2013 – April 2014

Non Regulatory

June 2, 2014

Oasmia’s Lead Product Paccal Vet®-CA1 Presented at the ACVIM Forum in Nashville on June 4

Non Regulatory

May 15, 2014

Oasmia recruits a new CFO

Non Regulatory

May 14, 2014

Oasmia’s production facility approved in the EU

Regulatory

March 31, 2014

Publication of change in the total number of shares and votes in Oasmia

Regulatory

March 31, 2014

Publication of change in the total number of shares and votes in Oasmia

Non Regulatory

March 25, 2014

Oasmia receives a new MSEK 40 bank loan

Non Regulatory

March 7, 2014

Oasmia successfully completes private placement of approximately SEK 72 million

Non Regulatory

March 6, 2014

Oasmia announces launch of private placement of new shares

Non Regulatory

March 6, 2014

Interim report for the period May 2013 – January 2014

Non Regulatory

February 28, 2014

Oasmia Receives FDA Conditional Approval For Its Lead Product Paccal Vet®-CA1

Non Regulatory

January 21, 2014

Oasmia’s Chief Financial Officer Weine Nejdemo retires